Evidence map›Paper›PMID 38707045›Full record

ReviewCureus2024

Hyponatremia With Anticonvulsant Medications: A Narrative Review.

Kristin Nicole Bembenick, Jibin Mathew, Michael Heisler, Harish Siddaiah, Peyton Moore, Christopher L Robinson, Adam M Kaye, Sahar Shekoohi, Alan D Kaye, Giustino Varrassi

Abstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kristin Nicole BembenickSchool of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA.
Jibin MathewDepartment of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Michael HeislerDepartment of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Harish SiddaiahDepartment of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Peyton MooreDepartment of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Christopher L RobinsonDepartment of Anesthesiology, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
Adam M KayeDepartment of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences University of the Pacific, Stockton, USA.
Sahar ShekoohiDepartment of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Alan D KayeDepartment of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Giustino VarrassiPain Medicine, Paolo Procacci Foundation, Rome, ITA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyponatremia is an adverse effect of many antiseizure medications (ASMs). It occurs with interference with the normal balance of electrolytes within the body. Various risk factors associated with the development of hyponatremia in patients taking these medications include age, gender, dosage, and combinations with other drugs. ASMs such as carbamazepine (CBZ), oxcarbazepine (OXC), and valproic acid have a higher risk of hyponatremia. Hyponatremia induced by an antiseizure medication can occur through various mechanisms depending on the drug's specific mechanism of action. Hyponatremia can be a potentially fatal side effect. Patients taking these medications need to be monitored closely for the signs and symptoms of hyponatremia. Acute hyponatremia, defined as developing in <48 hours, is more likely to show symptoms than chronic hyponatremia. Signs of acute hyponatremia include delirium, seizures, decerebrate posturing, and cerebral edema with uncal herniation. Chronic hyponatremia, defined as developing in >48 hours, can cause lethargy, dizziness, weakness, headache, nausea, and confusion. Hyponatremia is associated with longer hospital stays and increased mortality. Treatment varies based on the degree of severity of hyponatremia. Choosing a treatment option should include consideration of the drug causing the electrolyte disturbance, the patient's risk factor profile, and the severity of symptoms as they present in the individual patient. Healthcare providers should be aware of hyponatremia as a potential side effect of ASMs, the signs and symptoms of hyponatremia, the different treatment options available, and the potential complications associated with rapid correction of hyponatremia.

Indexed as

adhaedsepilepsyhyponatremiaseizuressodium

Identifiers

PMID38707045
PMCPMC11066697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.